News

Ellen Ritchie, MD, Weill Cornell Medical College, New York, NY, and colleagues recently analyzed patient-reported outcomes (PROs) in myelofibrosis or essential thrombocythemia for patients who participated in the MOST study to measure symptom...

On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...

In a presentation at the 2023 NCCN Annual Conference, Keith Argenbright, MD, Moncrief Cancer Institute in Fort Worth, TX, and Evelyn González, Fox Chase Cancer Center in Philadelphia, PA, described the benefits of mobile cancer screening...

Si-yu Cao, MD, Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Sichuan, China, and colleagues recently compared the effectiveness of adjuvant chemoradiotherapy (ACR) to adjuvant chemotherapy (AC) for...

At the 2023 ESMO Gynecological Cancers Congress in Barcelona, Spain, Mansoor Raza Mirza, MD, a clinical oncologist from Rigshospitalet in Denmark, presented data on nonimmunological achievements and the role of HER2, B53, and other molecular...

At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).

At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...

Aijun Qin, MD, and colleagues recently investigated the use of a prognostic ferroptosis-related long noncoding RNA (lncRNA) model based on the RNA gene CFAP58-DT for predicting the survival time of patients with endometrial cancer and to help...

A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.

At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...